Pfizer (PFE) CFO Dave Denton to depart; Cecile Guegan named interim CFO. Company reaffirms 2026 guidance. Key context for investors.
Pfizer (PFE) CFO Dave Denton to depart; Cecile Guegan named interim CFO. Key investor implications for capital allocation, R&D and cost-savings.
Pfizer lowers its 2025 revenue outlook and issues 2026 guidance; investors weigh pipeline, cost savings, and pricing agreements.
Pfizer (PFE) announces 4 regulatory approvals and 8 positive Phase 3 readouts in 2025; pipeline, financials, and investor risks summarized.
Pfizer (PFE) Q3 2025 revenue and earnings fell; net income $3.54B ($0.62). Company raised full‑year EPS guidance citing cost savings and pipeline progress.
Pfizer (PFE) secures a U.S. drug pricing agreement and acquires Metsera for $4.9B, bolstering its obesity pipeline and altering margin and capital priorities.